Kala Bio Inc KALA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KALA is a good fit for your portfolio.
News
-
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
-
KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Kala Pharmaceuticals Shares Rise Nearly 5% After FDA Fast Track Designation
Trading Information
- Previous Close Price
- $6.85
- Day Range
- $6.65–6.99
- 52-Week Range
- $5.10–19.35
- Bid/Ask
- $6.70 / $6.99
- Market Cap
- $19.26 Mil
- Volume/Avg
- 54 / 24,745
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA’smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 43
- Website
- https://www.kalarx.com
Valuation
|
Metric
|
KALA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.52 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
KALA
|
|---|---|
Quick Ratio | 6.13 |
Current Ratio | 6.33 |
Interest Coverage | −6.72 |
Quick Ratio
KALA
Profitability
|
Metric
|
KALA
|
|---|---|
Return on Assets (Normalized) | −49.95% |
Return on Equity (Normalized) | −217.57% |
Return on Invested Capital (Normalized) | −59.66% |
Return on Assets
KALA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ltvbkkxh | Dwgry | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qxsbqxnt | Rmrwbgs | $101.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kmdlgzdnh | Zhglpsg | $98.9 Bil | |
MRNA
| Moderna Inc | Snfmszfz | Wmhm | $39.7 Bil | |
ARGX
| argenx SE ADR | Vknlsljb | Nfb | $21.5 Bil | |
BNTX
| BioNTech SE ADR | Chgptjdn | Kqmv | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xdkzpclb | Fywlq | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vtcctjl | Jzcql | $17.2 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hhlqbtmsrr | Vlkwcl | $12.3 Bil | |
INCY
| Incyte Corp | Xdyjxcgz | Rqhzhr | $11.8 Bil |